Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CPC634 (CriPec® docetaxel) is effective in
the treatment of patients with advanced epithelial ovarian cancer who are resistant to prior
platinum-based chemotherapy
.